Marsha Moses

Q: What Schools Are Affiliated With Marsha Moses

Marsha Moses is affiliated with the following schools: Massachusetts Institute of Technology, Harvard University

Marsha Moses's AcademicInfluence.com Rankings

Marsha Moses

Law

#2779

World Rank

#3453

Historical Rank

Common Law

#148

World Rank

#160

Historical Rank

law Degrees

Download Badge

Marsha Moses's Degrees

Doctorate Medicine Harvard University

Why Is Marsha Moses Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Marsha A. Moses is an American physician who is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. Her research considers the biochemical mechanisms that are responsible for tumor growth and progression. She is a Fellow of the American Institute for Medical and Biological Engineering, the American Academy of Arts and Sciences and the American Association for the Advancement of Science.

(See a Problem?)

Marsha Moses's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma (1994) (3409)
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. (2009) (782)
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. (2010) (494)
Identification of an inhibitor of neovascularization from cartilage. (1990) (482)
The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL) (2001) (477)
Reactive oxygen generated by Nox1 triggers the angiogenic switch (2002) (472)
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. (1997) (466)
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. (2011) (436)
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. (2000) (398)
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. (2002) (397)
Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* (1997) (342)
Tissue engineering of autologous aorta using a new biodegradable polymer. (1999) (318)
Lipocalin 2 promotes breast cancer progression (2009) (314)
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. (2012) (312)
Advancing the field of drug delivery: taking aim at cancer. (2003) (299)
Dose-dependent response of FGF-2 for lymphangiogenesis. (2004) (285)
Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance* (1999) (284)
Increased incidence of matrix metalloproteinases in urine of cancer patients. (1998) (272)
Radiation therapy to a primary tumor accelerates metastatic growth in mice. (2001) (258)
The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients (2005) (256)
Microdeformational Wound Therapy: Effects on Angiogenesis and Matrix Metalloproteinases in Chronic Wounds of 3 Debilitated Patients (2006) (255)
Radiation abscopal antitumor effect is mediated through p53. (2003) (254)
The Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors (1997) (247)
ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage* (2004) (245)
Tumor-Derived Extracellular Vesicles Breach the Intact Blood Brain Barrier via Transcytosis. (2019) (233)
Nanoparticle elasticity directs tumor uptake (2018) (230)
Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. (1994) (228)
Troponin I is present in human cartilage and inhibits angiogenesis. (1999) (218)
The regulation of neovascularization of matrix metalloproteinases and their inhibitors. (1998) (201)
Making the cut: protease-mediated regulation of angiogenesis. (2006) (195)
Forty-Year Journey of Angiogenesis Translational Research (2011) (178)
Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome (2014) (168)
Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species (2008) (157)
Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy (2008) (156)
Molecular angiogenesis. (1999) (151)
Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling* (2003) (127)
Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin‐binding EGF‐like growth factor independently of protein kinase C (1998) (125)
HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. (2001) (125)
ICAM-1 as a molecular target for triple negative breast cancer (2014) (123)
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. (2006) (123)
Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing (1996) (121)
Lipocalin 2: A multifaceted modulator of human cancer (2009) (121)
Heparinase inhibits neovascularization. (1994) (115)
A metalloproteinase inhibitor as an inhibitor of neovascularization (1991) (114)
Increased Expression of Urinary Matrix Metalloproteinases Parallels the Extent and Activity of Vascular Anomalies (2005) (110)
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. (2009) (110)
Inhibitors of Angiogenesis (1991) (109)
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer (2013) (103)
Patch augmentation of the pulmonary artery with bioabsorbable polymers and autologous cell seeding. (2000) (99)
Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). (1994) (95)
ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer (2016) (92)
Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes (1992) (90)
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. (2004) (87)
Effect of pulse rate on collagen deposition in the tissue-engineered blood vessel. (2003) (86)
Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. (2010) (85)
Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. (2006) (84)
Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment (2008) (83)
Wound Healing Versus Regeneration: Role of the Tissue Environment in Regenerative Medicine. (2010) (81)
Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor (2007) (80)
The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. (1999) (76)
Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. (2014) (75)
Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. (1997) (74)
Structural and Functional Uncoupling of the Enzymatic and Angiogenic Inhibitory Activities of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) (2003) (73)
Biocompatible controlled release polymers for delivery of polypeptides and growth factors (1991) (69)
Vascular endothelial growth factor delays onset of failure in pressure–overload hypertrophy through matrix metalloproteinase activation and angiogenesis (2006) (69)
The importance of angiogenesis in the interaction between polymeric biomaterials and surrounding tissue. (2003) (65)
Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies (2014) (65)
Biocompatibility testing of novel multifunctional polymeric biomaterials for tissue engineering applications in head and neck surgery: an overview (2006) (64)
ADAM12 Transmembrane and Secreted Isoforms Promote Breast Tumor Growth (2011) (64)
Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease (2008) (63)
Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures (2001) (61)
Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. (2010) (60)
Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis (2019) (59)
Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks (2017) (56)
Ovarian cancer biomarkers: current options and future promise. (2008) (56)
Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. (1996) (55)
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation. (2020) (54)
Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel (2019) (53)
Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade (2014) (51)
The role of growth factors in vascular cell development and differentiation. (1995) (49)
Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. (2010) (48)
Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. (2010) (48)
Nanomaterial Preparation by Extrusion through Nanoporous Membranes. (2018) (48)
Lipocalin 2 expression is associated with aggressive features of endometrial cancer (2012) (48)
Adipocytes promote ovarian cancer chemoresistance (2019) (47)
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. (2011) (46)
Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer (2015) (44)
A critical role for matrix metalloproteinases in liver regeneration. (2008) (43)
Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. (2006) (42)
Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. (2012) (41)
Matrix metalloproteinases and their inhibitors in aqueous humor. (1996) (38)
Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. (2007) (37)
Effects of Metalloproteinase Inhibition in a Murine Model of Renal Ischemia-Reperfusion Injury (2010) (37)
Matrix metalloproteinases are elevated in the urine of patients with endometriosis. (2010) (36)
Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. (2006) (34)
The Anti-angiogenic Peptide, Loop 6, Binds Insulin-like Growth Factor-1 Receptor* (2010) (33)
Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer (2015) (33)
The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis (2015) (32)
ITGA2 as a potential nanotherapeutic target for glioblastoma (2019) (32)
ADAM12 induces estrogen-independence in breast cancer cells (2012) (31)
Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. (2013) (31)
Brainwashed by extracellular vesicles: the role of extracellular vesicles in primary and metastatic brain tumour microenvironment (2019) (29)
Identification of novel non‐invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network (2017) (29)
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. (2013) (28)
ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling (2017) (27)
Fetal partial urethral obstruction causes renal fibrosis and is associated with proteolytic imbalance. (1999) (27)
Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). (1996) (26)
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. (2011) (26)
The role of extracellular vesicles in the physiological and pathological regulation of the blood–brain barrier (2021) (24)
A RECURRENT CRANIOPHARYNGIOMA ILLUSTRATES THE POTENTIAL USEFULNESS OF URINARY MATRIX METALLOPROTEINASES AS NONINVASIVE BIOMARKERS: CASE REPORT (2007) (24)
Weight Loss‐Induced Calciphylaxis: Potential Role of Matrix Metalloproteinases (2003) (24)
Metalloproteinases and their roles in human cancer (2020) (24)
Cancer Nanomedicines in an Evolving Oncology Landscape. (2020) (24)
Potential of fluorescent metalloproteinase substrates for cancer detection. (2011) (23)
Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. (2012) (23)
Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. (1994) (22)
A cartilage-derived inhibitor of neovascularization and metalloproteinases. (1993) (22)
Matrix metalloproteinase‐2 (MMP‐2) expression and regulation by tumor necrosis factor alpha (TNFα) in the bovine corpus luteum (2005) (21)
Physical and Family History Variables Associated With Neurological and Cognitive Development in Sturge-Weber Syndrome. (2019) (21)
Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset. (2019) (21)
Endothelial cells as mechanical transducers: enzymatic activity and network formation under cyclic strain. (2004) (21)
Expression of MMPs and TIMPs in primary epithelial cell cultures of the upper aerodigestive tract seeded on the surface of a novel polymeric biomaterial. (2005) (21)
Molecular cloning and expression analysis of the cDNA encoding rat tissue inhibitor of metalloproteinase-4. (1998) (21)
Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer (2018) (21)
Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. (2005) (20)
Characterization of dormant and active human cancer cells by quantitative phase imaging (2017) (18)
[Cell proliferation and cellular activity of primary cell cultures of the oral cavity after cell seeding on the surface of a degradable, thermoplastic block copolymer]. (2005) (17)
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia (2012) (16)
Urinary Matrix Metalloproteinases and their Endogenous Inhibitors Predict Hepatic Regeneration after Murine Partial Hepatectomy (2004) (16)
Matrilin-1 Is an Inhibitor of Neovascularization* (2014) (16)
Bovine Membrane-Type 1 Matrix Metalloproteinase: Molecular Cloning and Expression in the Corpus Luteum1 (2002) (16)
BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. (2003) (16)
A role for antiangiogenic therapy in breast cancer (2004) (15)
Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. (2011) (14)
Cdc42-Dependent Transfer of mir301 from Breast Cancer-Derived Extracellular Vesicles Regulates the Matrix Modulating Ability of Astrocytes at the Blood–Brain Barrier (2020) (14)
The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells (2015) (14)
Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum (2003) (14)
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors (2015) (14)
A Facile Magnetic Extrusion Method for Preparing Endosome‐Derived Vesicles for Cancer Drug Delivery (2021) (13)
Angiogenic molecules and mechanisms in breast cancer (2000) (11)
Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines. (2018) (11)
Urine vascular biomarkers in Sturge–Weber syndrome (2013) (11)
Urinary kallikrein 10 predicts the incurability of gastric cancer (2017) (11)
Obituary: M. Judah Folkman (1933–2008) (2008) (11)
A Role for Cysteine-Rich 61 in the Angiogenic Switch During the Estrous Cycle in Cows: Regulation by Prostaglandin F2alpha1 (2011) (11)
Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins. (2015) (9)
Purification and characterization of two collagenase inhibitors from mouse sarcoma 180 conditioned medium (1994) (9)
Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro. (2007) (9)
Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study (2018) (9)
Metalloproteinase inhibition as a mechanism for the inhibition of angiogenesis. (1992) (9)
A quantitative method for screening and identifying molecular targets for nanomedicine (2017) (9)
Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib (2018) (9)
A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells. (2018) (9)
Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases (2015) (8)
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer (2020) (8)
Matrix metalloproteinase-2 (MMP-2) expression and regulation by tumor necrosis factor alpha (TNFalpha) in the bovine corpus luteum. (2005) (8)
Rationally Designed Antibody Drug Conjugates Targeting the Breast Cancer-Associated Endothelium. (2020) (8)
Quantitative phase imaging characterization of tumor-associated blood vessel formation on a chip (2018) (5)
MMPs in Biology and Medicine (2015) (5)
Establishment and biochemical characterization of primary cells of the upper aerodigestive tract. (2007) (5)
Matrix Metalloproteinases in the Urine and Tissue of Patients With Juvenile Polyps: Potential Biomarkers for the Presence of Polyps (2009) (4)
Biomarkers in Cancer (2010) (3)
Association of Longitudinal Changes in Symptoms and Urinary Biomarkers in Patients with Urological Chronic Pelvic Pain Syndrome (UCCPS): A MAPP Research Network Study. (2020) (3)
Advances in Brief HIF-1 a-mediated Up-Regulation of Vascular Endothelial Growth Factor , Independent of Basic Fibroblast Growth Factor , Is Important in the Switch to the Angiogenic Phenotype during Early Tumorigenesis 1 (2001) (3)
Control of low Km cyclic adenosine 3′,5′-monophosphate-phosphodiesterase in prostate and heart of adult and aged rats (1987) (3)
Prenatal urinary matrix metalloproteinase profiling as a potential diagnostic tool in fetal obstructive uropathy. (2010) (3)
Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. (2003) (3)
Multicenter Research Data of Epilepsy Management in Patients With Sturge-Weber Syndrome. (2021) (3)
Lipocalin 2 expression is associated with aggressive features of endometrial cancer (2012) (2)
Association between urinary biomarkers MMP-7/TIMP-2 and reduced renal function in children with ureteropelvic junction obstruction (2022) (2)
Abstract 5285: ADAM12: A novel mediator of tumor angiogenesis (2012) (2)
Proteomic Discovery of Noninvasive Biomarkers Associated With Sport-Related Concussions (2021) (2)
Abstract 4410: An ICAM-1-targeted, Lcn2 siRNA-encapsulating liposome as a potent anti-angiogenic agent for triple-negative breast cancer (2015) (2)
Quantitative Analysis of Different Cell Entry Routes of Actively Targeted Nanomedicines Using Imaging Flow Cytometry (2019) (2)
61 Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer (2015) (2)
Abstract 1293: Neutrophil gelatinase-associated lipocalin regulates the expression of angiogenic cytokines and VEGF in human breast and ovarian cancer cells (2010) (2)
Abstract 4828: Recapitulating mammary ductal carcinoma microenvironmentin vitrousing sacrificial bioprinting (2017) (2)
Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy. (2010) (1)
Abstract 892: Potential of urinary MMP-9/NGAL complex as a novel biomarker for the early detection of gastric cancer (2014) (1)
Abstract 2207: Using AFM to predict the specificity of tumor targeting nanomedicinein vivo (2016) (1)
Characterization of the anti-angiogenic effects of TIMP-4. (2004) (1)
Abstract 2818: Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels (2011) (1)
Mining the human urinary proteome biomarker discovery for human cancer and its metastases (2015) (1)
Abstract A53: ADAM12 contributes to the malignant potential of pancreatic cancer and may serve as a non-invasive biomarker for its detection (2016) (1)
Escape from breast tumor dormancy: The convergence of obesity and menopause (2022) (1)
Abstract 4950: Collagen, type I, alpha 1 (COL1A1): a potential urinary biomarker that can distinguish between benign prostate hyperplasia and localized prostate cancer (2016) (1)
exploring the role of ADAM12 in breast cancer (2006) (1)
Abstract 5808: The role of breast cancer-derived exosomes in brain metastasis (2017) (1)
Abstract 416: ADAM12 long and short isoforms promote breast tumor growth and metastasis via distinct mechanisms (2010) (1)
Extracellular matrix dynamics associated with tissue-engineered intravascular sclerotherapy. (2006) (1)
ADAM12: A Novel Mediator of Tumor Angiogenesis (2013) (1)
Abstract 711: Mechanistic implications of COL1A1 as a prostate cancer biomarker (2017) (0)
Biphasic Effects of TIMP-1 on Burkitt’s Lymphoma (2001) (0)
Abstract 2719: Non-invasive biomarker discovery for ovarian cancer (2010) (0)
P79 Assessing the utility of matrix-degrading enzymes as a biomarker for disease status and therapeutic efficacy in lung cancer (2007) (0)
Erratum to “Potential of Fluorescent Metalloproteinase Substrates for Cancer Detection” [Clin. Biochem. 44 (2011) 1434–1439] (2012) (0)
Abstract 173: Hypercholesterolemia induces angiogenesis and causes accelerated growth of breast tumorsin vivo. (2013) (0)
Abstract 1989: Breast cancer-derived exosomes modulate the endocytic pathway in brain endothelial cells (2019) (0)
Abstract A11: Adipocytes promote ovarian cancer cell survival in the presence of chemotherapeutic drugs (2015) (0)
Can Angiogenesis Regulatory Proteins Guide Ultra-early Detection and Therapy of Recurrent Human Cancer? (2007) (0)
P96: Portal hypertension due to early closure of ductus venosus (DV) in neonatal lambs: Possible implication in the pathogenesis of necrotizing enterocolitis (NEC) (2007) (0)
The MMP-9/NGAL complex plays a role in breast tumor growth and is present with high frequency in the urine of breast cancer patients (2005) (0)
ITGA2 as a potential nanotherapeutic target for glioblastoma (2019) (0)
Abstract 3188: Discovery and validation of non-invasive biomarkers for benign prostate hyperplasia and prostate cancer (2011) (0)
Urinary matrix metallproteinases as a marker for angiostatin production in mice (2000) (0)
Brain Vascular MalformaƟon ConsorƟum: Overview, Progress, and Future DirecƟons (2013) (0)
Abstract 2392: Transcriptional repression of VEGF by Znf24, a C2H2 zinc finger protein (2010) (0)
Abstract 5083: Using proteomics profiling to elucidate the interactions of breast cancer-derived exosomes with the blood-brain barrier (2018) (0)
Abstract 3433: Global proteomic analysis of urine using a label-free LC-MS/MS approach identifies potential biomarkers of metastatic breast cancer (2023) (0)
Abstract 5083: Adipocytes promote pancreatic cancer cell proliferation and progression (2015) (0)
Judah Folkman, M.D. February 24, 1933–January 14, 2008 (2008) (0)
Abstract 361: ZNF24 may modulate microvascular endothelial cell invasion by regulating MMP2 transcription. (2013) (0)
Abstract 2914: ITGA-2 is a novel therapeutic target for glioblastoma and high-grade gliomas (2018) (0)
Abstract 3135: Postmenopausal obese mammary adipocytes promote breast tumorigenesis via the LCN2/IL-6/STAT3 signaling axis (2022) (0)
R053: Biocompability Testing of Biomaterials for Tissue Engineering in the Aerodigestive Tract (2003) (0)
Abstract A44: The obesity and pancreatic cancer connection: Crosstalk between adipose, tumor, and stroma (2019) (0)
A role for CYR61 in ovarian cancer progression (2006) (0)
Abstract 5315: Identification of urinary proteome signatures associated with triple-negative breast cancer (2023) (0)
growth factor mRNA and protein in adult mouse brain Prolonged hypoxia increases vascular endothelial (2015) (0)
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo (2023) (0)
N ovel Delivery Systems in Cancer Chemotherapy (0)
during Early Tumorigenesis Factor , Is Important in the Switch to the Angiogenic Phenotype Growth Factor , Independent of Basic Fibroblast Growth-mediated Up-Regulation of Vascular Endothelial α HIF-1 Updated (2001) (0)
Anti-angiogenic and anti-tumor activities of PPARα ligands (2004) (0)
Effect of cell culture conditions on production of collagen XVII, MMP-2 and TIMP and on cellular growth of human dermal microvascular endothelial cells (HDMEC) (1997) (0)
Matrix metalloproteinases in patient urine as non-invasive surrogate markers for endometriosis (2007) (0)
Abstract 30: Modulating the angiogenic potential of human microvascular endothelial cells by an endogenous zinc finger transcription factor, ZNF24 (2014) (0)
Abstract LB-242: Oncosomes: Large bioactive particles secreted by prostate cancer cells (2010) (0)
In Vivo Expression of Cysteine-Rich 61 and Angiogenic Regulators in Bovine Ovarian Follicles. (2011) (0)
Abstract 4016: PIK3IP1 regulates prostate cancer cell migration and proliferation and is a noninvasive biomarker of the disease (2019) (0)
Abstract 2190: Brain-seeking extracellular vesicles derived from metastatic breast cancer cells modulate brain endothelial cell metabolism (2022) (0)
A role for neutrophil gelatinase-associated lipocalin in regulating tumor angiogenesis (2008) (0)
Zellproliferation und zelluläre Aktivität von Primärzellkulturen der Mundhöhle nach Oberflächenbesiedlung eines abbaubaren, thermoplastischen Blockcopolymers / Cell proliferation and cellular activity of primary cell cultures of the oral cavity after cell seeding on the surface of a degradable, ther (2005) (0)
and Activity of Vascular Anomalies Increased Expression of Urinary Matrix Metalloproteinases Parallels the Extent (2007) (0)
The Urinary Proteomic Profile Implicates Key Regulators for Urologic Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study (2021) (0)
Methode d'evaluation du risque de cancer du sein (2006) (0)
Abstract 2523: Endogenous Angiogenesis Inhibitors Prevent Adaptive Capillary Growth in Hypertrophying Myocardium (2006) (0)
Seeking diagnostic and prognostic biomarkers for childhood bacterial pneumonia in sub-Saharan Africa: study protocol for an observational study (2021) (0)
Abstract A49: Adipocytes promote ovarian cancer cell chemoresistance (2013) (0)
INCREASED INCIDENCE OF MATRIX METALLOPROTEINASES IN THE URINE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 201 (2005) (0)
Abstract 891: Urinary ADAM12 levels detect the presence of pancreatic cancer (2014) (0)
Abstract 2645: Obesity promotes tumor growth, reduces breast tumor latency and correlates with neovascularization: Therapeutic and diagnostic implications (2020) (0)
CCN1 (Cysteine Rich 61-Connective Tissue Growth Factor- Nephroblastoma Overexpressed) and the Expression of Integrins by Bovine Ovarian Follicles. (2012) (0)
Abstract 121: Mammary adipocytes drive breast tumor progression and angiogenesis via the VEGF/IL6/STAT3 signaling axis (2020) (0)
Therapeutic Targeting of Advanced Papillary and Anaplastic Thyroid Carcinoma by ICAM1 Antibody Drug Conjugates (2022) (0)
Abstract 5122: Obesity promotes tumor growth, reduces breast tumor latency and correlates with neovascularization (2018) (0)
Are CCN1 (Cysteine Rich 61-Connective Tissue Growth Factor-Nephroblastoma Overexpressed) and Integrin Receptor Subunits Expressed by KGN, an Ovarian Granulosa Tumor Cell Line? (2012) (0)
Shedding of Endomucin by Endothelial Cells under Inflammatory Conditions: Involvement of Matrix Metalloproteases (2015) (0)
Abstract 5133: Transcriptional repression of VEGF by ZNF24: Mechanistic studies and vascular consequencesin vivo (2011) (0)
Abstract 3892: BATF3 is a novel regulator of breast cancer cell invasion. (2013) (0)
A Facile Magnetic Extrusion Method for Preparing Endosome‐Derived Vesicles for Cancer Drug Delivery (Adv. Funct. Mater. 44/2021) (2021) (0)
MP68-03 EVALUATION OF CANDIDATE URINARY BIOMARKERS FOR UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS) (2016) (0)
PRESENCE OF MATRIX METALLOPROTEINASES IN THE URINE AND TISSUE OF PATIENTS WITH JUVENILE POLYPS: 132* (2005) (0)
Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer (2015) (0)
Nanoparticle elasticity directs tumor uptake (2018) (0)

This paper list is powered by the following services:

Other Resources About Marsha Moses

en.wikipedia.org

What Schools Are Affiliated With Marsha Moses?

Marsha Moses is affiliated with the following schools:

Marsha Moses's Academic­Influence.com Rankings